Skip to main content
IronOxCLINIC

Iron Infusion Types: Why Phosphate Risk Matters

Clinical director:
Dr Ros
Published
Reading time
5 min read
An earlier clinical review by Dr Rukhsana Jabar is recorded; a dated clinical review of the current text is not recorded.
Open notebook, pen and glasses on a table beside a mug; illustrative image

A Ferinject infusion contains ferric carboxymaltose. Monofer contains ferric derisomaltose. These are different intravenous iron preparations, and the choice should be explained as part of your treatment assessment.

One issue worth discussing is phosphate. Product choice is a clinical decision, so this article does not tell you to request a particular brand or assume that your clinic offers every formulation.

Why phosphate comes up in an iron appointment

Phosphate is involved in normal body function. The UK medicines regulator has warned that ferric carboxymaltose can cause symptomatic low phosphate and, in some cases, bone complications.

The MHRA safety update advises phosphate monitoring for people receiving repeated high doses, long-term treatment or those with relevant risk factors. It also asks clinicians to advise patients to seek help for new musculoskeletal symptoms or worsening tiredness, which can be confused with symptoms of iron deficiency.

This makes follow-up questions important. Feeling tired after treatment should not automatically be dismissed, or automatically interpreted as needing another infusion.

Ask which medicine you are being offered

Before treatment, ask which preparation is planned and why. NICE recommends that discussions about tests and treatments cover options, benefits and risks, and support a joint decision. These questions can help you take part:

  1. Which preparation is planned, and why is it being considered for me?
  2. Which results support treatment and the dose?
  3. Does my history, including earlier IV iron, affect the phosphate-monitoring or follow-up plan?
  4. Which symptoms should prompt medical advice, and where should I seek it?
  5. When should we review my response before considering further treatment?

If you have details of earlier infusions, bring the product name and date if available. The MHRA asks that suspected adverse-reaction reports include the brand name and treatment dates.

What the product information says about phosphate

The current product information for both medicines lists hypophosphataemia (low blood phosphate) as a possible adverse effect, but uses different frequency categories:

ProductActive ingredientHypophosphataemia frequency category in its product information
FerinjectFerric carboxymaltoseCommon (at least 1 in 100 and fewer than 1 in 10)
MonoferFerric derisomaltoseUncommon (at least 1 in 1,000 and fewer than 1 in 100)

These are categories from each product's own prescribing information, which draws on its clinical-trial and post-marketing data. They are not a direct head-to-head estimate, a prediction for an individual or evidence that either product is risk-free. The MHRA discusses a possible higher risk of persistent low phosphate and osteomalacia with ferric carboxymaltose than with other IV iron formulations; that regulatory statement does not remove the need to consider Monofer's own product information and the person's circumstances.

The Ferinject Summary of Product Characteristics lists hypophosphataemia as common and advises monitoring in defined repeated high-dose, long-term or risk-factor contexts. The Monofer Summary of Product Characteristics lists it as uncommon. The MHRA safety update, including its September 2026 note, advises medical review for relevant symptoms and monitoring/reassessment in specified ferric-carboxymaltose risk contexts. These sources do not determine which product is appropriate for you.

Our iron infusion side-effects article covers the wider discussion, and what to expect at an infusion explains the appointment pathway. Tell staff promptly about symptoms during administration.

Follow-up and when to seek help

IronOx’s appointment guide says the treating team gives aftercare instructions; follow the instructions for your own appointment. For ferric carboxymaltose, the MHRA advises seeking medical advice for new musculoskeletal symptoms or worsening tiredness, which may be confused with iron deficiency. It recommends phosphate monitoring in specified repeated higher-dose, long-term or risk-factor contexts, and re-evaluation if low phosphate persists.

Severe allergic reactions to IV iron can be life-threatening. If you develop sudden swelling of the mouth, tongue or throat, difficulty breathing, or collapse, call 999. The Resuscitation Council UK's first-aid guidance says to call 999 when anaphylaxis is suspected.

If you are considering an infusion, discuss your results, the reason for treatment, product options, risks and follow-up with a healthcare professional. The NICE shared decision making guideline recommends discussing benefits and risks and agreeing a joint plan; it does not point to one particular product. If you want to discuss the IronOx service, its booking page offers a consultation option.

Sources

Frequently asked questions

What is in Ferinject?

Ferinject contains ferric carboxymaltose, an intravenous iron preparation. Ask your clinician why a particular preparation is appropriate for you.

Should I ask about phosphate before an infusion?

Yes. Ask whether your treatment history and risk factors mean phosphate monitoring is needed and what symptoms to report afterwards.